News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Targeted Use of OSI Pharmaceuticals, Inc.'s Tarceva Effective for Some Tumors
September 15, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 13 (Reuters) - Using OSI Pharmaceuticals Inc's Tarceva pill to target tumours carrying specific genetic mutations significantly extended the lives of some people with lung cancer, Spanish researchers said on Saturday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Europe
MORE ON THIS TOPIC
Obesity
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
September 8, 2026
·
2 min read
·
Heather McKenzie
cardiovascular disease
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
September 8, 2026
·
2 min read
·
Gabrielle Masson
Drug Development
Roivant’s pulmonary hypertension drug shines with ‘blowout’ Phase 2 data
September 8, 2026
·
1 min read
·
Michael Gibney
Neuroscience
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
September 8, 2026
·
2 min read
·
Tristan Manalac
